JC
Therapeutic Areas
Amicus Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Galafold (migalastat) | Fabry Disease (Pediatric, 2 to <12 yrs) | Phase 3 |
| Pombiliti + Opfolda (AT-GAA) | Pompe Disease (IOPD, 0 to <18 yrs) | Phase 3 |
| DMX-200 | Focal Segmental Glomerulosclerosis (FSGS) | Phase 3 |
| Observational Study | Fabry Disease (Women's study) | Observational |
| Observational Registry | Fabry Disease (EU) | Observational |
Leadership Team at Amicus Therapeutics
BL
Bradley L. Campbell
President and Chief Executive Officer
SH
Simon Harford
Chief Financial Officer
DC
David Clark
Chief People Officer
TP
Tiffany Patrick
Chief Patient Officer
SM
Sébastien Martel
Chief Business Officer
ES
Ellen S. Rosenberg
Chief Legal Officer
JP
Jeffrey P. Castelli
Chief Development Officer
SA
Stephen Arnold
Chief, Head of Global Rare Disease
PO
Pat O'Sullivan
Chief Technical Operations Officer
JW
Jill Weimer
Chief Science Officer